期刊文献+

Adjuvant Pelvic Radiotherapy vs.Sequential Chemoradiotherapy for High-Risk StageⅠ-ⅡEndometrial Carcinoma 被引量:3

Adjuvant Pelvic Radiotherapy vs.Sequential Chemoradiotherapy for High-Risk StageⅠ-ⅡEndometrial Carcinoma
下载PDF
导出
摘要 Objective To explore if the addition of adjuvant chemotherapy with paclitaxel and carboplatin to radiotherapy confers an advantage for overall survival (OAS), and progression free survival (PFS); to assess the incidence of relapses over standard pelvic radiotherapy; and to evaluate the related toxicity in high-risk stage I-II endometrial carcinoma Methods Medical records were reviewed to identify high-risk stage I-1I endometrial carcinoma cases treated in the Clinical Oncology and Nuclear Medicine department between 2002 and 2008 with adjuvant radiotherapy alone (arm Ⅰ)(57 patients) or with sequential carboplatin (AUCS-6) and paclitaxel (135-175 mg/m^2) with radiotherapy (arm Ⅱ) (51 patients). Radiotherapy was performed through the four-field box technique at doses of 45-50 Gy (1.8 Gy/day × 5 days/week). Results The toxicity was manageable and predominantly hematologic with a grade 3 neutropenia and thrombocytopenia in 9.8% and 6% of the patients in arm Ⅰ and arm Ⅱ, respectively, without febrile neutropenia. All patients experienced hair loss. Chernoradiotherapy arm was associated with a lower incidence rate of relapse (9.8% vs. 22.7%). After a median follow-up period of 48 months, the 5-year OAS and PFS rates for chemoradiotherapy-treated patients were significantly more favorable than those who did not receive chemotherapy (P=0.02 and 0.03, respectively). In arm I, the OAS and PFS rates were 73.7% and 66.7% compared with those in arm II, whose rates were 90.2% and 84.3%. Conclusions Adjuvant chemoradiation with paclitaxel and carboplatin improved the survival rates and decreased the recurrence rates in patients with high-risk stage Ⅰ-Ⅱ endometrial carcinoma. Chemotherapy was associated with an acceptable rate of toxicity. However, a prospective study with a larger number of patients is needed to define a standard adjuvant treatment for high-risk stage Ⅰ-Ⅱ endometrial carcinoma. Objective To explore if the addition of adjuvant chemotherapy with paclitaxel and carboplatin to radiotherapy confers an advantage for overall survival(OAS),and progression free survival(PFS);to assess the incidence of relapses over standard pelvic radiotherapy; and to evaluate the related toxicity in high-risk stageⅠ-Ⅱendometrial carcinoma Methods Medical records were reviewed to identify high-risk stageⅠ-Ⅱendometrial carcinoma cases treated in the Clinical Oncology and Nuclear Medicine department between 2002 and 2008 with adjuvant radiotherapy alone(armⅠ)(57 patients) or with sequential carboplatin(AUC5-6) and paclitaxel(135-175 mg/m^2) with radiotherapy(armⅡ)(51 patients).Radiotherapy was performed through the four-field box technique at doses of 45-50 Gy(1.8 Gy/day×5 days/week). Results The toxicity was manageable and predominantly hematologic with a grade 3 neutropenia and thrombocytopenia in 9.8% and 6% of the patients in armⅠand armⅡ,respectively,without febrile neutropenia.All patients experienced hair loss. Chemoradiotherapy arm was associated with a lower incidence rate of relapse(9.8% vs.22.7% ).After a median follow-up period of 48 months,the 5-year OAS and PFS rates for chemoradiotherapy-treated patients were significantly more favorable than those who did not receive chemotherapy(P=0.02 and 0.03,respectively).In armⅠ,the OAS and PFS rates were 73.7% and 66.7% compared with those in armⅡ,whose rates were 90.2% and 84.3% . Conclusions Adjuvant chemoradiation with paclitaxel and carboplatin improved the survival rates and decreased the recurrence rates in patients with high-risk stageⅠ-Ⅱendometrial carcinoma.Chemotherapy was associated with an acceptable rate of toxicity. However,a prospective study with a larger number of patients is needed to define a standard adjuvant treatment for high-risk stageⅠ-Ⅱendometrial carcinoma.
出处 《Clinical oncology and cancer researeh》 CAS CSCD 2012年第3期168-171,共4页
关键词 stage I-II high-risk endometrial cancer adjuvant radiotherapy adjuvant sequential chemoradiotherapy 子宫内膜癌 化疗 风险 放疗 盆腔 放射治疗 中性粒细胞 序贯
  • 引文网络
  • 相关文献

参考文献27

  • 1Plataniotis G,Castiglione M,ESMO Guidelines Working Group. Endometrial cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Annals of Oncology,2010,(Suppl 5):v41-v45.
  • 2Creasman TW,Odicino F,Maisonneuve P. Carcinoma of the corpus uteri.26 th Annual Report on the Results of Treatment in Gynecological Cancer[J].International Journal of Gynecology and Obstetrics,2006,(suppl.1):105-143.
  • 3Morrow CP,Bundy BN,Kurman RJ. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium:a Gynecologic Oncology Group Study[J].Gynecologic Oncology,1991.55-65.
  • 4Keys HM,Roberts JA,Brunetto V. A phase III trial of surgery with or without adjuvant external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma:a Gynecologic Oncology Group Study[J].Gynecologic Oncology,2004.744-751.
  • 5Creutzberg LC,vanPutten JLW,Koper CP. Surgery and post operative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma:multicentre randomized trial[J].The Lancet,2000.1401-1411.
  • 6Jolly S,Vargas C,Kumar T. Vaginal brachytherapy alone:An alternative to adjuvant whole pelvis radiation for early stage endometrial cancer[J].Gynecologic Oncology,2005.887-892.
  • 7Randall ME,Filiaci VL,Muss H. Gynecologic Oncology Group Study Randomized phase III trial of whole abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma:a Gynecologic Oncology Group study[J].Journal of Clinical Oncology,2006.36-44.
  • 8Fleming GF,Brunetto VL,Cella D. Phase III trial of doxorubicin and cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma:a Gynecologic Oncology Group study[J].Journal of Clinical Oncology,2004.2159-2166.
  • 9Santin AD,Bellone S,O'Brien TJ. Current treatment options for endometrial cancer[J].Expert Review of Anticancer Therapy,2004.679-689.
  • 10Sovak MA,Dupont J,Hensley ML. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer:a large retrospective study[J].International Journal of Gynecological Cancer,2007.197-203.

同被引文献32

引证文献3

二级引证文献13

;
使用帮助 返回顶部